CD Biosynsis is committed to reducing the cost of adriamycin production by using synthetic biology techniques to enable the mass production of adriamycin in microbial cell factories.
Adriamycin belongs to the anthracycline class of antibiotics, a drug that acts on DNA and is widely used in chemotherapy. Adriamycin has broad-spectrum antitumor effects and is commonly used in the treatment of leukemia, gastric cancer, lung cancer, and many other cancers. Currently, adriamycin is mainly produced by chemical and semi-chemical methods. That is, the intermediate product is first obtained through biological fermentation, and then adriamycin is prepared through separation and crystallization. However, the production of adriamycin by semi-chemical synthesis method is long-cycle, difficult, and easy to causes environmental pollution. Therefore, it is important to find a method that can quickly meet the industrial production of adriamycin. The biosynthesis of adriamycin has the advantages of low cost and low pollution and is promising as a novel way to produce adriamycin.
Figure 1. Overall scheme used for enhanced production of daunorubicin and doxorubicin from S. peucetius. (Shrestha B, et al., 2019)
Based on synthetic biology strategies, we are able to optimize the microbial production process of adriamycin and maximize the potential of the adriamycin biosynthesis pathway.
Based on the resolution of the adriamycin biosynthetic pathway, we are able to reconstruct the biosynthetic pathway of adriamycin in microbial factories using genetic engineering.
We are able to use metabolic engineering to breed the strains used for adriamycin production.
We work to design genetic circuits that precisely control gene expression based on a multigene synergistic strategy.
Development of Microbial Chassis for Adriamycin Production
We are able to transfer the gene for synthesizing adriamycin into a specified microbial factory by genomic integration or plasmid carriage to achieve adriamycin production in engineered bacteria. The following are the microbial chassis that has been used for the production of adriamycin. Please contact us directly if you have other chassis of interest for adriamycin production.
| Escherichia coli | Pichia pastoris | Streptomyces peucetius | Saccharomyces cerevisiae |
Breeding of Adriamycin-Producing Bacteria
We are able to breed adriamycin-producing bacteria based on metabolic engineering strategies to improve the production of adriamycin. We are able to overexpress genes in the rate-limiting step of adriamycin production, knock out negatively regulated genes, or block branched metabolic genes in the adriamycin biosynthetic pathway.
Modular Co-Culture for Adriamycin Production
We are able to divide the adriamycin biosynthetic pathway into different modules, and reconstitute and express the different module genes within the same or different species of engineered microorganisms, respectively. We are able to optimize medium composition and design dynamically changing culture conditions to achieve high-volume production of adriamycin.
CD Biosynsis can develop tailored tools and customized approaches to harness the power of synthetic biology to drive adriamycin production and meet the needs of customers in a variety of industries.
CD Biosynsis provides the most comprehensive and efficient solutions for synthetic biology workflows. We are committed to helping our customers solve all problems encountered in adriamycin production to advance their applications in a wide range of fields. Each of our deliverables will undergo a rigorous quality inspection test to ensure the reliability and accuracy of the results. If you are interested in our services or have any further questions, please do not hesitate to contact us.
Reference
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.
Home